Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin")

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 2, 2006, Pages 528-536

  Fukutome, Mika ^a   Maebayashi, Katsuya ^a   Nasu, Sachiko ^a   Seki, Kaori ^a   Mitsuhashi, Norio ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Dual inhibition; HER family; Radiosensitization; Trastuzumab; ZD1839

Indexed keywords

CELLS; CYTOLOGY; IMAGE ENHANCEMENT; MEDICAL IMAGING; ONCOLOGY; PROTEINS;

DUAL INHIBITION; HER FAMILY; RADIOSENSITIZATION; TRASTUZUMAB; ZD1839;

RADIOTHERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; TRASTUZUMAB;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; INTRACELLULAR TRANSPORT; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION INJURY; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; VULVA CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; ENZYME ACTIVATION; G2 PHASE; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE KINASE 2; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 33748300698     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.036     Document Type: Article

References (35)

1. Buchholz T.A., Tu X., Ang K.K., et al. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 104 (2005) 676-681
2. Rubin Grandis J., Melhem M.F., Gooding W.E., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 799-801
3. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
4. Dancey J. Epidermal growth factor receptor inhibitors in clinical development. Int J Radiat Oncol Biol Phys 58 (2004) 1003-1007
5. Normanno N., Bianco C., De Luca A., et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10 (2003) 1-21
6. Marty M., Cognetti F., Maraninchi D., et al., M77001 study group. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment. J Clin Oncol 23 (2005) 4247-4250
7. Lu Y., Zi X., and Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108 (2004) 334-341
8. Akimoto T., Hunter N.R., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5 (1999) 2884-2890
9. Lee C.M., Lee R.J., Hammond E., et al. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol 93 (2004) 209-214
10. Lammering G., Valerie K., Lin P.S., et al. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 72 (2004) 276-273
11. Zingg D., Riesterer O., Fabbro D., et al. Differential activation of the phosphatidylinositol 3′-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells. Cancer Res 64 (2004) 5398-5406
12. Schmidt-Ullrich R.K., Contessa J.N., Dent P., et al. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 7 (1999) 321-330
13. Dent P., Yacoub A., Contessa J., et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159 (2003) 283-300
14. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
15. Akimoto T., Nonaka T., Harashima K., Ishikawa H., and Mitsuhashi N. Selective inhibition of survival signal transduction pathways enhanced radiosensitivity in human esophageal cancer cell lines in vitro. Anticancer Res 24 (2004) 811-819
16. Shintani S., Li C., Mihara M., et al. Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol 40 (2004) 43-51
17. Huang S.M., Li J., Armstrong E.A., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839. (Iressa). Cancer Res 62 (2002) 4300-4306
18. Harari P.M., and Huang S.M. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11 (2001) 281-289
19. Moasser M.M., Basso A., Averbuch S.D., et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61 (2001) 7184-7188
20. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
21. Kwok T.T., and Sutherland R.M. Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer 64 (1991) 251-254
22. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
23. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1876-1878
24. Chang G.C., Hsu S.L., Tsai J.R., et al. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 68 (2004) 1453-1464
25. Shintani S., Li C., Mihara M., et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107 (2003) 1030-1037
26. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10 (1998) 262-267
27. Brazil D.P., and Hemmings B.A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26 (2001) 657-664
28. Contessa J.N., Hampton J., Lammering G., et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21 (2002) 4032-4041
29. Franke T.F., Kaplan D.R., Cantley L.C., et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275 (1997) 665-668
30. Edwards E., Geng L., Tan J., et al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 62 (2002) 4671-4677
31. Zhou H., Kim Y.S., Peletier A., et al. Effect of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58 (2004) 344-352
32. Formento P., Hannoun-Levi J.M., Fischel J.L., et al. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. Eur J Cancer 40 (2004) 2837-2844
33. Mellinghoff I.K., Tran C., and Sawyers C.L. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 62 (2002) 5254-5259
34. Normanno N., Campiglio M., De L.A., et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13 (2002) 65-72
35. Moulder S.L., Yakes F.M., Muthuswamy S.K., et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61 (2001) 8887-8895